We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
Read MoreHide Full Article
Key Takeaways
QuidelOrtho's core diagnostics growth outside China offers support despite weaker near-term visibility.
QDEL expects China challenges through 2026 as pricing uncertainty and faster inventory cuts weigh on demand.
QuidelOrtho had $123.4 million in cash versus $2.89 billion in debt after $143.6 million in cash use.
QuidelOrtho Corporation (QDEL - Free Report) is showing resilience in its core diagnostics businesses, but the investment case remains constrained by worsening visibility in China, uncertain respiratory demand and financial pressure. The mix leaves investors weighing operational progress against risks that could limit earnings recovery.
Cost savings and product investment provide support, yet weaker cash conversion and elevated leverage keep the near-term risk-reward profile unfavorable.
QDEL’s Core Growth Offers Some Support
Second-quarter revenues outside China grew 6% at constant currency, reflecting healthier trends across much of QuidelOrtho’s portfolio. Labs revenues outside China increased 9%, while Immunohematology revenues outside China rose 5%.
Management expects those two core businesses outside China to grow roughly 3%-5% in aggregate during the second half of 2026. Their recurring-revenue characteristics provide some stability while other parts of the business remain more volatile.
Image Source: Zacks Investment Research
China Weakness Clouds QDEL’s Near-Term Visibility
China revenues fell 18.7% on a reported basis and 23.3% at constant currency in the second quarter. Slower distributor purchases ahead of evolving national in-vitro diagnostics pricing guidelines weighed on demand, particularly in Labs.
Customers also reduced inventories more quickly than management had anticipated after quarter-end. With final pricing rules and implementation timing still uncertain, QuidelOrtho expects China-related challenges to persist through the remainder of 2026.
QDEL’s Cost Actions Help but Margins Stay Pressured
Adjusted EBITDA increased 21% year over year to $129 million in the second quarter, showing that productivity and expense-control efforts are having an impact. The Optimization Plan continues to target approximately $50 million of net cost savings through 2027.
That progress has not removed margin pressure. Adjusted gross margin contracted 130 basis points to 44.4%, with lower China volumes contributing to an unfavorable geographic mix. Further cost execution remains important if revenue headwinds persist.
NULEXA Gives QDEL a Longer-Term Growth Option
QuidelOrtho is shifting its molecular strategy toward NULEXA following the April acquisition of LEX Diagnostics. The company is advancing manufacturing scale-up, supply-chain readiness and commercial launch preparations, with customer placements and test utilization expected to build as the 2026-2027 respiratory season progresses.
NULEXA also provides a platform for future menu expansion, but adoption is not assured. Competition remains substantial. Abbott Laboratories (ABT - Free Report) reported $3.1 billion in second-quarter Diagnostics sales, while Danaher Corporation (DHR - Free Report) reported 7% Diagnostics sales growth, highlighting the scale of established diagnostics rivals.
QDEL’s Leverage and Cash Use Keep Risk Elevated
QuidelOrtho ended the second quarter with $123.4 million in cash and cash equivalents against $2.89 billion of total debt. During the first six months of 2026, operating activities used $143.6 million of cash compared with cash generation in the prior-year period.
Weak cash conversion increases the importance of delivering on cost savings and improving working-capital efficiency. Elevated leverage also leaves less room for execution setbacks if China weakness or softer respiratory demand lasts longer than expected.
QDEL’s Bearish Signal Supports a Cautious View
QDEL’s core growth, cost actions and NULEXA opportunity provide reasons to monitor the stock, but they do not yet outweigh the company’s weaker earnings visibility, margin pressure and balance-sheet risks. The investment case remains better suited to a cautious stance until operating improvements translate into stronger cash performance.
The stock currently carries a Zacks Rank #5 (Strong Sell). QDEL also has a Value Score of B, but its Growth Score of F and Momentum Score of F signal weak growth and momentum characteristics, while the VGM Score of D points to an unfavorable combined profile. Given that Style Scores are designed to complement the Zacks Rank, the current mix does not provide a strong signal for buying the shares despite the relatively favorable value reading.
View the Zacks #1 Rank List
Image: Bigstock
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
Key Takeaways
QuidelOrtho Corporation (QDEL - Free Report) is showing resilience in its core diagnostics businesses, but the investment case remains constrained by worsening visibility in China, uncertain respiratory demand and financial pressure. The mix leaves investors weighing operational progress against risks that could limit earnings recovery.
Cost savings and product investment provide support, yet weaker cash conversion and elevated leverage keep the near-term risk-reward profile unfavorable.
QDEL’s Core Growth Offers Some Support
Second-quarter revenues outside China grew 6% at constant currency, reflecting healthier trends across much of QuidelOrtho’s portfolio. Labs revenues outside China increased 9%, while Immunohematology revenues outside China rose 5%.
Management expects those two core businesses outside China to grow roughly 3%-5% in aggregate during the second half of 2026. Their recurring-revenue characteristics provide some stability while other parts of the business remain more volatile.
Image Source: Zacks Investment Research
China Weakness Clouds QDEL’s Near-Term Visibility
China revenues fell 18.7% on a reported basis and 23.3% at constant currency in the second quarter. Slower distributor purchases ahead of evolving national in-vitro diagnostics pricing guidelines weighed on demand, particularly in Labs.
Customers also reduced inventories more quickly than management had anticipated after quarter-end. With final pricing rules and implementation timing still uncertain, QuidelOrtho expects China-related challenges to persist through the remainder of 2026.
QDEL’s Cost Actions Help but Margins Stay Pressured
Adjusted EBITDA increased 21% year over year to $129 million in the second quarter, showing that productivity and expense-control efforts are having an impact. The Optimization Plan continues to target approximately $50 million of net cost savings through 2027.
That progress has not removed margin pressure. Adjusted gross margin contracted 130 basis points to 44.4%, with lower China volumes contributing to an unfavorable geographic mix. Further cost execution remains important if revenue headwinds persist.
NULEXA Gives QDEL a Longer-Term Growth Option
QuidelOrtho is shifting its molecular strategy toward NULEXA following the April acquisition of LEX Diagnostics. The company is advancing manufacturing scale-up, supply-chain readiness and commercial launch preparations, with customer placements and test utilization expected to build as the 2026-2027 respiratory season progresses.
NULEXA also provides a platform for future menu expansion, but adoption is not assured. Competition remains substantial. Abbott Laboratories (ABT - Free Report) reported $3.1 billion in second-quarter Diagnostics sales, while Danaher Corporation (DHR - Free Report) reported 7% Diagnostics sales growth, highlighting the scale of established diagnostics rivals.
QDEL’s Leverage and Cash Use Keep Risk Elevated
QuidelOrtho ended the second quarter with $123.4 million in cash and cash equivalents against $2.89 billion of total debt. During the first six months of 2026, operating activities used $143.6 million of cash compared with cash generation in the prior-year period.
Weak cash conversion increases the importance of delivering on cost savings and improving working-capital efficiency. Elevated leverage also leaves less room for execution setbacks if China weakness or softer respiratory demand lasts longer than expected.
QDEL’s Bearish Signal Supports a Cautious View
QDEL’s core growth, cost actions and NULEXA opportunity provide reasons to monitor the stock, but they do not yet outweigh the company’s weaker earnings visibility, margin pressure and balance-sheet risks. The investment case remains better suited to a cautious stance until operating improvements translate into stronger cash performance.
The stock currently carries a Zacks Rank #5 (Strong Sell). QDEL also has a Value Score of B, but its Growth Score of F and Momentum Score of F signal weak growth and momentum characteristics, while the VGM Score of D points to an unfavorable combined profile. Given that Style Scores are designed to complement the Zacks Rank, the current mix does not provide a strong signal for buying the shares despite the relatively favorable value reading.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.